NMD Pharma
PrivateLast Round
Series B
Nov 15, 2023
Total Funding Raised
$170.61M
Company Overview
NMD Pharma is a biotechnology company that develops a first-in-class platform of small molecule therapies for the treatment of severe neuromuscular disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NMD Pharma Comparables
Compare NMD Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Augustine Therapeutics | 77% | |
| Edgewise Therapeutics | 74% | |
| Epirium Bio | 70% |
NMD Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 15, 2023 | ||||
| Series A Extension | Feb 15, 2022 | ||||
| Series A | Mar 23, 2018 | ||||
| Seed | Jun 1, 2016 |
Key People
Founding team and executive leadership
NMD Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lundbeck Foundation | Series A Extension |
| Roche Venture Fund | Series B, Series A, Series A Extension |
| Lundbeckfonden BioCapital | Series B |
| Roche Venture Fund | Series B, Series A, Series A Extension |
| Novo Holdings | Grant, Series B, Seed, Series A, Series A Extension |
| Inkef Capital | Series B, Series A Extension, Series A |
| Capnova | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2026
Presented SYNAPSE-CMT study data at the MDA Conference.
- Mar 10, 2026
Top-line safety and efficacy data released for ignaseclant in Phase 2a study.
Recent news
Latest coverage and updates
- attends_eventJun 17, 2026
NMD Pharma attended event 2026 Peripheral Neuroscience Association (PNS) Annual Meeting on Jun 13th '26.
NMD Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NMD Pharma's valuation, stock price, and market status.
Is NMD Pharma a public or private company?
NMD Pharma is a private company.
What is the current stock price of NMD Pharma?
NMD Pharma is a private company with no public stock price. No recent secondary market data is available.
How much is NMD Pharma worth (valuation)?
Valuation information for NMD Pharma is not publicly available.
Can I buy NMD Pharma stock?
NMD Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was NMD Pharma's last funding round?
NMD Pharma's most recent funding round was Series B Extension on November 15, 2023.
Who are the main investors in NMD Pharma?
Key investors in NMD Pharma include Inkef Capital.
Will NMD Pharma IPO soon?
No public IPO plans have been announced for NMD Pharma.
How can I track NMD Pharma secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NMD Pharma's secondary market activity and sign up for updates.